These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38212977)

  • 1. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
    Li X; Lu W; Kharitonenkov A; Luo Y
    J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
    Mellor HR
    Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monomeric/dimeric forms of Fgf15/FGF19 show differential activity in hepatocyte proliferation and metabolic function.
    Williams CM; Harper Calderon J; E H; Jimenez Y; Barringer K; Carbonaro M; Molina-Portela MDP; Thurston G; Li Z; Daly C
    FASEB J; 2021 Feb; 35(2):e21286. PubMed ID: 33484478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver.
    Cui G; Martin RC; Jin H; Liu X; Pandit H; Zhao H; Cai L; Zhang P; Li W; Li Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):136. PubMed ID: 29973237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
    Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R
    Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
    Tao Z; Cui Y; Xu X; Han T
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
    Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
    Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
    [No Abstract]   [Full Text] [Related]  

  • 8. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.
    Zhou M; Wang X; Phung V; Lindhout DA; Mondal K; Hsu JY; Yang H; Humphrey M; Ding X; Arora T; Learned RM; DePaoli AM; Tian H; Ling L
    Cancer Res; 2014 Jun; 74(12):3306-16. PubMed ID: 24728076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
    Zhou M; Luo J; Chen M; Yang H; Learned RM; DePaoli AM; Tian H; Ling L
    J Hepatol; 2017 Jun; 66(6):1182-1192. PubMed ID: 28189755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
    Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
    Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
    Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
    Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
    Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
    PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
    Lang L; Shull AY; Teng Y
    Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis.
    Alvarez-Sola G; Uriarte I; Latasa MU; Urtasun R; Bárcena-Varela M; Elizalde M; Jiménez M; Rodriguez-Ortigosa CM; Corrales FJ; Fernández-Barrena MG; Berasain C; Avila MA
    Dig Dis; 2017; 35(3):158-165. PubMed ID: 28249259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF19-
    Raja A; Park I; Haq F; Ahn SM
    Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma.
    Shin JY; Ahn SM
    J Transl Med; 2021 Apr; 19(1):138. PubMed ID: 33794926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
    Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
    Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
    Wu AL; Coulter S; Liddle C; Wong A; Eastham-Anderson J; French DM; Peterson AS; Sonoda J
    PLoS One; 2011 Mar; 6(3):e17868. PubMed ID: 21437243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential.
    Xie H; Alem Glison DM; Kim RD
    Expert Opin Investig Drugs; 2022 Apr; 31(4):393-400. PubMed ID: 34913780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.